Encycle raises $2.85 million in start-up funding

Guest Contributor
October 10, 2015

Encycle Therapeutics Inc has completed financing of $2.85 million to support development of its nacellin platform chemistry and advance its therapeutics pipeline. The investment in the Toronto-based firm — spun off from the Univ of Toronto in collaboration with MaRS Innovation — will allow it to build on its relationships with pharmaceutical companies and position itself for series A financing or additional strategic partnerships. The funding round was led by Takeda Ventures Inc and includes Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund. Potential applications for Encycles' chemistry include so-called undruggable proteins which cannot be targeted with conventional therapeutics. Its synthetic method for generating drug-like cyclic peptides is called nacellins, which are membrane permeable and "orally bioavailable". The technology was developed by a Univ of Toronto research team led by Dr Andrei Tudin with support from many players along the Ontario-Quebec life sciences corridor....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.